Безопасност при вдишване на водороден газ при здрави мишкиНаучно Изследване

INTRODUCTION

Ischemia reperfusion injury may negatively affect outcomes in a variety of clinical settings, including following myocardial infarction, stroke, and cardiac arrest. One of the mechanisms of ischemia reperfusion injury is the generation of reactive oxygen species, including the hydroxyl radical (•OH). •OH reacts indiscriminately with nucleic acids, lipids and proteins, causing direct cellular injury and stimulating apoptosis. It has been recently shown that molecular dihydrogen (H₂) gas selectively reduces •OH,¹² and modifies several inflammatory pathways.³ There is mounting evidence to support its clinical benefits in treating ischemia reperfusion injury. In rodents, post-ischemic H₂ inhalation has been shown to diminish cerebral infarct size and improve neurologic scores in rats following middle cerebral artery occlusion.¹ Several rat studies have demonstrated improvement in survival and outcomes in models of cardiac arrest associated with hydrogen administration.⁴⁵⁶⁷ In swine, inhalation of H₂ diminishes cerebral injury volume and improves clinical outcomes in models of simulated perinatal asphyxia⁸ and cardiopulmonary bypass-related ischemia.⁹ Similarly, inhaled H₂ improves sequelae of ischemia reperfusion injury in animal models of liver¹⁰ and lung¹¹ injury.

More recently, inhaled H₂ has reached clinical use in Japan. The first study described the 18-hour administration of 2% H₂ to 5 patients resuscitated from cardiac arrest and undergoing simultaneous targeted temperature management; 4/5 patients exhibited a normal neurologic examination (cerebral performance category 1) at hospital discharge and no environmental hazards were reported.¹² A large, randomized trial of H₂ therapy in post-cardiac arrest syndrome is underway.¹³ Further, inhaled H₂ was studied in adults presenting with ST-segment elevation myocardial infarction, randomized to treatment with or without 2% H₂ (via face mask) for 24 hours post-reperfusion, with H₂-treated patients demonstrating significantly improved ventricular ejection fraction at 6-month follow-up.¹⁴ Finally, patients who were randomized to breathing 3% H₂ gas for 1 hour twice a day for 7 days following stroke demonstrated improved clinical stroke scores and a diminished volume of injury by brain MRI compared with similarly-treated controls (n = 25 patients/group).¹⁵ To our knowledge, no data are available regarding the effects of inhaled H₂ in healthy humans.

The purpose of this work was to screen for adverse effects of inhaled hydrogen gas in healthy animals in order to inform a future phase I safety trial in humans.

MATERIALS AND METHODS

Animals

The following protocol was approved by the Institutional Animal Care and Use Committee at Boston Children’s Hospital, USA (approved number 18-01-3536) on January 25, 2018. IGS female mice (n = 50, 10-week-old, CD-1, Charles River Labs, Wilmington, MA, USA) were acclimated to our rodent housing facility in ambient air for 96 hours in a 12-hour alternating light-dark cycle at room temperature with free access to food and water. Animals were then placed into a custom gas-tight chamber (Biospherix, Parish, NY, USA) with a capacity to house five mouse cages (25 mice) (https://links.lww.com/MGAR/A30). Within this chamber, mice were exposed to certified medical air with or without hydrogen gas (Praxair, Inc., Danbury, CT, USA) for a 72-hour period (n = 25 per group). The source gas (3.2% hydrogen, 21% oxygen, balance nitrogen) was titrated to maintain a target inhaled gas concentration of approximately 2.4%, and H₂ concentration was quantified at the exhaust port of the chamber (Eagle 2, RKI Instruments, Union City, CA, USA). In the control group, medical air was flowed into the chamber at a set flow rate (3 L/min). Mice were housed in litters of five mice each and had free access to food and water during this time. The following endpoints were quantified at the end of the exposure period.

Neurobehavioral assessment

Each mouse underwent a neurologic and behavioral assessment using a well-established neurodevelopmental and behavioral examination (known as SHIRPA, an acronym for SmithKline Beecham, Harwell, Imperial College, Royal London Hospital, Phenotype Assessment)¹⁶¹⁷ both before and after the exposure period. All tests were completed by a team member blinded to treatment allocation. This battery of tests includes a scoring system to grade muscular, cerebellar, sensory, neuropsychiatric and autonomic functions (article 1). Additionally, each mouse was weighed before and after the exposure period.

Serologic and histologic examinations

After the exposure period and SHIRPA evaluation, mice were anesthetized with 0.5–2% isoflurane (Patterson Veterinary, Greeley, CO, USA) via face mask in oxygen. Pre-sacrifice blood was withdrawn in a subset of animals (n = 5) via terminal left ventricular puncture for evaluation of serologic markers of renal and hepatic injury, coagulopathy, as well as arterial blood gas analysis. In all animals, all major organs were then removed, formalin-fixed, stained by hematoxylin and eosin, and evaluated by light microscopy (Keyence BZ-X710 All-in-One Fluorescence Microscope, Keyence, Itasca, IL, USA) by a pathologist blinded to treatment allocation. In order to examine for any subtle damage (i.e., invisible to light microscopy) to the airways, samples of the mid-trachea were fixed, embedded, sectioned (80 nm-thick), and examined by electron microscopy (Tecnai G2 Spirit BioTWIN Electron Microscope, FEI Company, Hillsboro, OR, USA) by a pathologist blinded to treatment allocation in a subset of animals (n = 5 per group).

Statistical analysis

Body weight was compared prior to and following the exposure period separately for each group by paired t-test. Similarly, the total SHIRPA score and locomotor scores (a subportion of the SHIRPA score) were compared prior to and following exposure by paired t-test. The change in locomotor score was compared between groups using an unpaired t-test after normality was confirmed (D’Agostino & Pearson normality test). All serologic examinations were compared between groups by Mann–Whitney U test. All analyses were performed in GraphPad Prism (Prism version 7.0d, GraphPad Software, La Jolla, CA, USA).

RESULTS

All animals in both groups survived the 72-hour gas exposure. The time-averaged measured hydrogen concentration at the exhaust port was 2.27% (95% confidence interval (CI) 2.26–2.29%) (https://links.lww.com/MGAR/A31). Gas flow rate in the hydrogen group (6.5 ± 0.3 L/min) was significantly higher than in the control group (3.0 ± 0.0 L/min, P < 0.0001).

Effect of inhaled hydrogen gas on the SHIRPA scoring of healthy mice

The average pre-exposure body weight was 29.15 ± 0.41 g in the hydrogen group and 29.51 ± 0.46 g in the control group (P = 0.56). There was no significant change in body weight prior to versus following exposure in either the hydrogen or the control group (Figure 1A). There was no significant change in the pre- versus post-exposure SHIRPA score in either hydrogen- or control-exposed animals (Figure 1B). However, a subset of the total SHIRPA score enumerates the number of squares that a mouse contacts within 30 seconds, known as the locomotor activity score. This score was similar between groups pre-exposure (though mathematically higher in the hydrogen-exposed group, P = 0.56), and significantly decreased in hydrogen-exposed mice (P < 0.0001), and significantly increased in control mice (P = 0.0048; Figure 1Cversus post-exposure change was significant between groups (P < 0.0001, Figure 1D). Following exposure, all animals in both groups exhibited normal skin coloring, activity level, transfer arousal, exhibited signs of neither hyperactivity nor hypoactivity (Additional article 1).

Effect of inhaled hydrogen gas on the serologic parameters of healthy mice

There were no statistically significant differences between hydrogen-exposed and control mice in markers of liver or renal injury, including alkaline phosphatase, alanine aminotransferase, total bilirubin, blood urea nitrogen and serum creatinine. The white blood cell concentration, hemoglobin concentration, and platelet count were also similar between groups, as was arterial pH, arterial partial pressure of carbon dioxide, and the ratio of arterial oxygen tension to fraction of inspired oxygen (P > 0.05 for all comparisons; Figure 2).

Effect of inhaled hydrogen gas on the histology of healthy mice

There was no evidence of edema, neutrophilic or lymphocytic infiltration, or microscopic structural injury to the trachea, lungs, heart, brain, spleen, kidney, small intestine, or liver tissue in either group, and all tissues revealed normal cellular and microvascular architecture. No animal in either group exhibited signs of histologic injury by light microscopy (Figure 3). On the whole, there was no evidence of injury to airway epithelial cells by electron microscopy; in two animals exposed to hydrogen gas there was an increase in the prominence of secretory vesicles in respiratory epithelium, though nuclear, mitochondrial and ciliary structures remained intact (Figure 4).

DISCUSSION

We found that the administration of inhalational ~2% H₂ gas for 72 hours is generally benign in healthy rodents, with no evidence for serologic or histologic injury to any major organs or to blood components. Perhaps the most surprising finding was the decrease in locomotor activity as quantified within the so-named subportion of the SHIRPA test, although there was no overall difference in SHIRPA scoring between groups. Notably, all animals exhibited normal skin coloring, activity level, transfer arousal, exhibited signs of neither hyperactivity nor hypoactivity, and had normal weight, making the clinical significance of this finding uncertain. The other potentially important finding was the increased presence of secretory vacuoles in the hydrogen group; this finding lacked any histologic indicators of injury and is most likely due to the increased flow rate of dry gas within the hydrogen relative to the control group.

The primary purpose of this study was to inform which endpoints might be important to examine with rigor as part of a future phase I safety trial in healthy patients. Although no safety animal study has been previously performed per se, several animal and human studies have examined for adverse effects of hydrogen albeit in combination with treatment of an injury (i.e., the equivalent of a combined phase I/IIa trial), with few noarticle findings. For example, the stroke trial mentioned above describes a battery of testing including hematology and serum chemistries, showing no difference between control- and hydrogen-treated patients over a 14-day period following exposure.¹⁵ Because hydrogen is an inhaled gas, it is important to note that at least based on our screening test, hydrogen does not appear to interfere with lung function or to cause significant airway reactions. Although we did not examine for this, it is also theoretically possible that hydrogen may interfere with biological processes that depend on oxyradical formation, such as leukocyte killing or cytokine generation.¹⁸ However, it has also been suggested that hydrogen treatment may improve survival in models of septic shock due to other effects, such that this may in fact be beneficial in cases of severe sepsis.¹⁸ Finally, because hydrogen has been shown by several groups to ameliorate brain injury, the identification of neurocognitive effects of the drug in healthy patients may be important to inform the results of any future neurocognitive outcomes. Our findings of decreased spontaneous locomotor activity were consistent among animals and are statistically convincing. However, the fact that animals did not appear ill in any way, ate and drank normally, and had normal skin coloring and other reassuring neurologic signs makes this finding difficult to interpret in isolation. A phase I safety trial would be a reasonable place to inquire regarding symptoms and to identify any true motor weaknesses related to hydrogen administration, however unlikely they may be.

Limitations

Our study had several limitations. First, we did not quantify serum or tissue H₂ concentrations, instead quantifying the concentration of H₂ of inspired gas within the holding chamber. This was primarily due to the challenges of blood sampling in mice, and it has also been demonstrated that serum concentrations of H₂ reach a peak of ~10 μM within minutes of inhalation in human and fall rapidly following discontinuation of its administration.¹⁹ Second, we studied only female mice, precluding identification of gender-specific effects of the gas. Third, we measured bloodwork in a small subset of animals and were therefore underpowered to detect anything but consistent and large changes in any parameter. Fourth, we tested only a single dose and duration of hydrogen exposure, precluding any conclusions regarding the safety of a higher dose or longer duration of hydrogen administration. Finally, given the high number of endpoints that we measured (27 SHIRPA endpoints and 12 blood tests), we had an 86% likelihood of identifying a statistically significant difference between groups. This may in itself account for the differences we noted in locomotor activity.

Conclusion

Hydrogen gas does not appear to cause significant adverse effects when administered to healthy mice for 72 hours, with the possible exception of decreased spontaneous locomotor activity. Future phase I studies should consider the inclusion of a neurologic screening examination.

Acknowledgements

We thank Dana-Farber/Harvard Cancer Center in Boston, MA, USA for the use of the Rodent Histopathology Core, which provided tissue processing and staining. We also thank Maria Ericsson and the Electron Microscopy Facility at Harvard Medical School, USA for processing and imaging electron microscopy images.